Eli Lilly (NYSE:LLY) announced today that it made a $4.5 billion investment to create the Lilly Medicine Foundry in Indiana. The new center offers capabilities for advanced manufacturing and drug development. Lilly expects to gain new ways to produce medicines while also scaling up manufacturing of medicines for clinical trials. Its first-of-its-kind facility combines research…

Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…

Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the…

Over the past three months, the pharma sector has seen a string of investments in manufacturing facilities, especially in Europe. While the European economy lost momentum in 2023 owing to a high cost of living, weak external demand, and monetary tightening, the prospects for growth remain stronger with the EU GDP growth forecast to improve…

Eli Lilly and Company has recently received its third FDA rejection for the year 2023. The most recent came for lebrikizumab, the company’s investigational treatment for atopic dermatitis. FDA made the decision following an inspection of a third-party contract manufacturing organization. The agency had no complaints concerning the clinical data, safety, or labeling of lebrikizumab,…

Eli Lilly just wrapped up its acquisition of Versanis Bio in a $1.9 billion deal, the pharma giant announced today. The deal marks Lilly’s latest move to build up its pipeline of potential obesity and diabetes treatments, which promises to be a notable growth area for the company. Lilly recently completed its submission of tirzepatide…

A pair of weight-loss drugs —  semaglutide and tirzapatide — could reshape the way we view and treat obesity, according to a Moody’s report dated May 18. The ratings firm notes that Novo Nordisk could benefit from a first-mover advantage in the obesity market as it now has two novel weight loss drugs on the…

Eli Lilly and Company (NYSE:LLY) will invest an additional $1.6 billion and create roughly 200 new jobs at two new manufacturing sites within LEAP Innovation Park in Boone County, Indiana. In all, the company has earmarked $3.7 billion for the facilities and plans to create a total of about 700 new jobs. Examples of job…

The state of California has established a $50 million collaboration over a decade with the generic drug manufacturer Civica. The goal of the collaboration is to create affordable state-branded generic insulin. Qualified individuals may obtain a 10-mL vial of generic insulin for $30 or less. California plans to provide a pack containing five prefilled 3…

Paris-based Sanofi (Nasdaq:SNY) is the fastest company to reduce insulin prices. The pharmaceutical behemoth said it would cut  the list price of Lantus (insulin glargine injection) by 78%. Lantus is its most commonly prescribed insulin in the U.S. Moreover, Sanofi will implement a $35 cap on out-of-pocket expenses for users of the insulin. Sanofi has also…